Samsung Medison debuts AI-powered ob/gyn ultrasound system

AuntMinnie.com staff writers

Jan 31, 2025

Korea-based Samsung Medison has launched a new AI-powered ob/gyn ultrasound system in the U.S.

The company debuted Samsung Z20 at the Society for Maternal-Fetal Medicine (SMFM) 2025. The system features Live ViewAssist, a real-time deep learning tool that enhances precision and simplifies advanced obstetrical exams, according to the firm. Its other capabilities include automatic identification and labeling, real-time quality evaluation, and measurements.

The device is designed to reduce the risk of work-related musculoskeletal disorders, Samsung Medison said, adding that it also addresses the challenges of diagnosing patients with a high body mass index.

Also at SMFM, Sonio joined Samsung to showcase its cloud-based ultrasound reporting and image management software. Samsung acquired Sonio last year.

Samsung Medison

Smfm Ultrasound Ai Fetal Thumbnail

AI assistance improves CHD detection on prenatal ultrasound

January 31, 2025

(A,B) Images from an initial ultrasound examination showed no identifiable lesions and received a consensus ultrasound category of US-1. Nearly the entire liver is visualized, with minimal shadowing (“s”, A and B), and the examination received consensus result of VIS-A. The AFP level was 7.1 ng/mL on assessment six months before the ultrasound, 9.1 ng/mL on assessment three months before examination, and 14.2 ng/mL on assessment on exam day. The AFP result was thus assessed as positive based on a progressive increase on two consecutive tests. The atient was considered to have negative surveillance result according to LI-RADS Ultrasound Surveillance v2017, but positive surveillance result according to LI-RADS Ultrasound Surveillance v2024. (C-D) Axial arterial-phase (C) and portal-venous phase (D) T1-weighted images from subsequent gadoxetic acid-enhanced MRI show a 2-cm arterial-phase hyperenhancing observation (arrow, C) with portal-venous washout (arrow, D) in segment 7. This observation was classified on MRI as LR-5, thus meeting the present study’s reference standard for diagnosis of HCC. The mass is located in the periphery of the liver, an anatomic area where ultrasound visualization can be challenging due to shadowing.

LI-RADS ultrasound surveillance version 2024 improves HCC detection

January 22, 2025

Images depict a 49-year-old female participant with cryptogenic cirrhosis who presented with a 3.2-cm liver lesion. This biopsy-confirmed hepatocellular carcinoma (HCC) with an initial categorization of Liver Imaging Reporting and Data System (LI-RADS) category LR-4 (probably HCC) at CT was upgraded to LR-5 (definitely HCC) at contrast-enhanced ultrasound (CEUS). (A) Precontrast CT images in the liver show vague hypoattenuation in the medial left hepatic lobe (arrows). (B) Arterial phase images demonstrate no definite arterial phase hyperenhancement (arrows). (C) Washout and an enhancing capsule (arrows) on a late-phase image resulted in an LR-4 categorization. (D) B-mode ultrasound shows a round hypoechoic nodule (arrows). (E) An early-phase CEUS image shows clear arterial-phase hyperenhancement (arrows); (F) No washout at one minute (arrows), and (G) late, mild washout at four minutes (arrows) resulted in a CEUS LR-5 categorization.

CEUS resolves indeterminate CT, MRI liver observations

January 21, 2025

Ultrasound Portable

POCUS useful for diagnosis of retained conception tissue

January 15, 2025

AI assistance improves CHD detection on prenatal ultrasound

By Amerigo Allegretto

AI boosts detection of major congenital heart defects (CHDs) on prenatal ultrasound, suggest findings presented at the Annual Pregnancy Meeting of the SMFM.

January 31, 2025

Smfm Ultrasound Ai Fetal Thumbnail

LI-RADS ultrasound surveillance version 2024 improves HCC detection

By Amerigo Allegretto

The 2024 version of the LI-RADS Ultrasound Surveillance system improves detection of hepatocellular carcinoma (HCC) over earlier iterations.

January 22, 2025

(A,B) Images from an initial ultrasound examination showed no identifiable lesions and received a consensus ultrasound category of US-1. Nearly the entire liver is visualized, with minimal shadowing (“s”, A and B), and the examination received consensus result of VIS-A. The AFP level was 7.1 ng/mL on assessment six months before the ultrasound, 9.1 ng/mL on assessment three months before examination, and 14.2 ng/mL on assessment on exam day. The AFP result was thus assessed as positive based on a progressive increase on two consecutive tests. The atient was considered to have negative surveillance result according to LI-RADS Ultrasound Surveillance v2017, but positive surveillance result according to LI-RADS Ultrasound Surveillance v2024. (C-D) Axial arterial-phase (C) and portal-venous phase (D) T1-weighted images from subsequent gadoxetic acid-enhanced MRI show a 2-cm arterial-phase hyperenhancing observation (arrow, C) with portal-venous washout (arrow, D) in segment 7. This observation was classified on MRI as LR-5, thus meeting the present study’s reference standard for diagnosis of HCC. The mass is located in the periphery of the liver, an anatomic area where ultrasound visualization can be challenging due to shadowing.

CEUS resolves indeterminate CT, MRI liver observations

By Amerigo Allegretto

Contrast-enhanced ultrasound (CEUS) can resolve some high-risk indeterminate liver observations initially seen on CT or MRI.

January 21, 2025

Images depict a 49-year-old female participant with cryptogenic cirrhosis who presented with a 3.2-cm liver lesion. This biopsy-confirmed hepatocellular carcinoma (HCC) with an initial categorization of Liver Imaging Reporting and Data System (LI-RADS) category LR-4 (probably HCC) at CT was upgraded to LR-5 (definitely HCC) at contrast-enhanced ultrasound (CEUS). (A) Precontrast CT images in the liver show vague hypoattenuation in the medial left hepatic lobe (arrows). (B) Arterial phase images demonstrate no definite arterial phase hyperenhancement (arrows). (C) Washout and an enhancing capsule (arrows) on a late-phase image resulted in an LR-4 categorization. (D) B-mode ultrasound shows a round hypoechoic nodule (arrows). (E) An early-phase CEUS image shows clear arterial-phase hyperenhancement (arrows); (F) No washout at one minute (arrows), and (G) late, mild washout at four minutes (arrows) resulted in a CEUS LR-5 categorization.

POCUS useful for diagnosis of retained conception tissue

By Amerigo Allegretto

Point-of-care ultrasound (POCUS) can be a useful tool for diagnosing the presence of retained conception tissue.

January 15, 2025

Ultrasound Portable

AI guidance leads to better LUS image acquisition by novice users

By Amerigo Allegretto

Healthcare professionals who are not sonography experts can successfully acquire lung ultrasound (LUS) images with AI assistance.

January 15, 2025

Ultrasound Probe2 Social

Ultrasound ablation is effective for treating hyperparathyroidism

By Amerigo Allegretto

Ultrasound-guided thermal ablation techniques are safe and effective in treating patients with secondary hyperparathyroidism.

January 7, 2025

Ultrasound images depict a 63-year-old man who underwent radiofrequency ablation (RFA) for the treatment of secondary hyperparathyroidism. (A–D) 2D images show four hyperplastic parathyroid glands on the right and left sides (marked with crosshairs). The numbers near the crosshairs represent the number of measured trails. (E) Ultrasound-guided infusion of isolation fluid (arrowheads) around the hyperplastic parathyroid gland to protect vital organs such as the trachea (Tr), carotid arteries (CA), and recurrent laryngeal nerve pathway area (arrow). F) Ultrasound-guided RFA of the hyperplastic parathyroid gland. (G) Immediate postoperative contrast-enhanced ultrasound shows no contrast enhancement in the ablation area. The ablation procedures for the other three parathyroid glands were the same as those described above. Image courtesy of the RSNA,

RFA successful for treating malignant thyroid nodules

By Amerigo Allegretto

Radiofrequency ablation (RFA) can successfully treat malignant thyroid nodules with minimal adverse events.

December 13, 2024

What can we do to increase global access to imaging?

By Josh Sokol, MD

Outreach and philanthropy will be central themes at RSNA 2024. Ahead of the congress, teleradiologist Josh Sokol, MD, explains why the radiology community must work together to improve access to imaging.

December 1, 2024

The clinical team perform an ultrasound scan at the Nyankunde Hospital, the Democratic Republic of the Congo, where Warren Cooper, MD, has performed operations ranging from repairing broken bones to craniotomies for over a decade.

Inquest into neonatal death highlights ultrasound errors

A radiologist and a sonographer failed to diagnose critical conditions in two pregnant women, including a twin baby who died three days after birth, a report has revealed.

November 27, 2024

Digital Justice Scales

CEUS-based radiomics model aids in breast cancer diagnosis

By Amerigo Allegretto

A contrast-enhanced ultrasound (CEUS)-based radiomics model could help accurately diagnose breast cancer.

November 26, 2024

Ultrasound Scanner Computerized 400 (1)

Ultrasound-based deep learning models aid thyroid nodule prediction

By Amerigo Allegretto

A deep learning-based framework incorporating ultrasound images and clinical data can help in thyroid nodule prediction.

November 25, 2024

Elastography shows tissue stiffness in athletes with low-back pain

By Amerigo Allegretto

Shear-wave elastography shows tissue stiffness in athletes with low-back pain, which could help guide rehabilitation strategies.

November 22, 2024

Page 1 of 513